<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04140773</url>
  </required_header>
  <id_info>
    <org_study_id>2019-01699</org_study_id>
    <nct_id>NCT04140773</nct_id>
  </id_info>
  <brief_title>The Effect of D-serine as add-on Therapy in Recent-onset Psychosis</brief_title>
  <acronym>DROP</acronym>
  <official_title>The Effect of D-serine as add-on Therapy in Recent-onset Psychosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dragos Inta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Psychiatric Hospital of the University of Basel</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In psychotic disorders, negative symptoms and cognitive impairment are difficult to treat&#xD;
      with antipsychotics, which are mostly effective for positive symptoms. However, it is&#xD;
      important that negative symptoms and cognitive impairment are treated as well, as they both&#xD;
      play a large part in the acute episode and long-term course of schizophrenia outcome.&#xD;
      Previous studies have used D-serine as add-on treatment in patients with psy-chotic disorders&#xD;
      and high-risk patients, with positive results. So far, no study has investigated the effects&#xD;
      in a sample of recent-onset psychosis patients.&#xD;
&#xD;
      Therefore, this study will include 30 patients (18-50 years old) with recent-onset psychosis.&#xD;
      In addition to their regular treatment, patients will receive either D-serine (2 g/d) or&#xD;
      placebo for 6 weeks. D-serine is an amino-acid naturally occurring in the brain which is&#xD;
      prescription-free available as nutritional supplement.&#xD;
&#xD;
      The primary outcome measure is total score on the Positive and Negative Syndrome Scale&#xD;
      (PANSS). Secondary measure-ments include PANSS subscales, neurocognitive tests, (f)MRI, and&#xD;
      EEG&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total symptom severity</measure>
    <time_frame>change from baseline to 6 weeks</time_frame>
    <description>total score on the Positive and Negative Syndrome Scale (PANSS). Lower scores indicate better outcome (min. 30 - max. 120).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subscales symptom severity</measure>
    <time_frame>change from baseline to 6 weeks</time_frame>
    <description>Subscores (5-factor model) on the Positive and Negative Syndrome Scale (PANSS). Lower scores indicate better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptom severity and treatment response</measure>
    <time_frame>change from baseline to 6 weeks</time_frame>
    <description>measured with the Clinical Global Impression Scale (CGI), lower scores indicate a better outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resting-state microstates</measure>
    <time_frame>change from baseline to 6 weeks</time_frame>
    <description>measured with resting-state electroencephalography (EEG). large-scale neural networks are investigated with EEG microstates Ocillations in the theta-band (4-7 Hz) and gamma-band (&gt;30 Hz) will be assessed.&#xD;
measured with resting-state electroencephalography (EEG). Ocillations in the theta-band (4-7 Hz) and gamma-band (&gt;30 Hz) will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mismatch Negativity (MMN)</measure>
    <time_frame>change from baseline to 6 weeks</time_frame>
    <description>measured with EEG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intelligence</measure>
    <time_frame>change from baseline to 6 weeks</time_frame>
    <description>Part of neurocognitive testing. Higher scores indicate better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Attention and processing speed</measure>
    <time_frame>change from baseline to 6 weeks</time_frame>
    <description>Part of neurocognitive testing. Higher scores indicate better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Executive functioning</measure>
    <time_frame>change from baseline to 6 weeks</time_frame>
    <description>Part of neurocognitive testing. Higher scores indicate better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Memory</measure>
    <time_frame>change from baseline to 6 weeks</time_frame>
    <description>Part of neurocognitive testing. Higher scores indicate better outcome.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Psychotic Disorder</condition>
  <arm_group>
    <arm_group_label>D-serine group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral administration of 2g D-serine per day, for 6 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral administration of 2g Placebo (Mannitol) per day, for 6 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>D-serine</intervention_name>
    <description>Capsule D-serine</description>
    <arm_group_label>D-serine group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Capsule D-serine</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18-50&#xD;
&#xD;
          -  Recent onset psychosis (&lt; 5 years of overt psychotic symptoms)&#xD;
&#xD;
          -  Able to read and understand study procedures and participant's information&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clozapine use&#xD;
&#xD;
          -  Suicidal ideation&#xD;
&#xD;
          -  Psychotic disorders and symptoms associated with general medical conditions or&#xD;
             substance abuse&#xD;
&#xD;
          -  BMI &gt; 30&#xD;
&#xD;
          -  Renal impairment (history and creatin levels (&lt; 80 ug/L for woman and &lt; 97 ug/L for&#xD;
             men))&#xD;
&#xD;
          -  Hearing impairment&#xD;
&#xD;
          -  Current or past (&lt; 6 months) enrolment in another clinical trial with the primary&#xD;
             outcome to improve symptoms&#xD;
&#xD;
          -  Pregnant or lactating women (pregnancy test)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dragos Inta</last_name>
    <phone>+ 41 61 328 6128</phone>
    <email>Dragos.Inta@upk.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>UPK Basel</name>
      <address>
        <city>Basel</city>
        <state>Basel-Stadt</state>
        <zip>4002</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dragos Inta</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 18, 2019</study_first_submitted>
  <study_first_submitted_qc>October 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 28, 2019</study_first_posted>
  <last_update_submitted>October 8, 2021</last_update_submitted>
  <last_update_submitted_qc>October 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Psychiatric Hospital of the University of Basel</investigator_affiliation>
    <investigator_full_name>Dragos Inta</investigator_full_name>
    <investigator_title>Prof. Dr. med.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psychotic Disorders</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

